N/A N=108 Occlusion Balloon vs. 5FR Ureteral Catheter
Kidney Stones
Primary: Number of Participants With Ureteral Stone Fragments Identified Endoscopically — 2; 8 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=24 Drainage of Malignant Extrinsic Ureteral Obstruction Using the Memokath Ureteral Stent
Ureteral Obstruction
Primary: Mean Stent Dwell Time — 17; 3.97 months
N/A N=24 The RELIEF™ Ureteral Stent - Assessment of Retrograde Urinary Reflux and Distal Coil Bladder Position
Ureteral Obstruction
Primary: Incidence of Bladder Irritation Symptoms (e.g. Frequency, Urgency, Nocturia, Urine Leakage...) Associated With the RELIEF Stent. — 51.95 Units on a scale
Phase 4 N=181 Treatment of Symptoms After Stent Placement for Urinary Tract Obstruction
Ureteral Obstruction
Primary: Ureteral Stent Symptom Questionnaire Score Up to 24 Hours Prior to Stent Insertion — 1.76; 1.84; 2.02; 1.93 score on a scale
N/A N=90 Ureteral Stents Versus Percutaneous Nephrostomy for Initial Urinary Drainage
Children · Obstructive Uropathy · Acute Renal Failure
Primary: Period to Return to Normal Creatinine — 2.22; 2.18 days
Phase 4 N=77 Therapeutic Merit of Solifenacin in the Mitigation of Ureteral Stent-induced Pain and Lower Urinary Tract Symptoms
Flank Pain · Urinary Bladder, Overactive
Primary: Change in Post-ureteroscopy Stent-induced Pain — 4.61; 3.11 units on a scale
N/A N=63 Plastic vs. Covered Metal vs. Uncovered Metal Biliary Stents for the Management of Malignant Biliary Obstruction
Pancreatic Cancer
Primary: Assess the Occlusion Rates, Attempted Surgical Resection or Death of Plastic, Covered, and Uncovered Biliary Stents in Patients Presenting With Malignant Biliary…
N/A N=219 Better Lithotripsy and Ureteroscopy Evaluation of Stenting (BLUES)
Renal Stone · Ureteral Stone
Primary: Change in Patient-Reported Outcomes Measurement Information System (PROMIS®) Scores of Pain-intensity at 7 to 10 Days — 4.28; 2.92 T-score — p=0.26
Phase 3 N=104 The Effect of Terazosin and Tolterodine on Ureteral Stent Related Symptoms
Disorder of Urinary Stent
Primary: Lower Urinary Tract Symptoms (LUTS) — 11.12; 4.39; 7.21; 5.58 units on a scale
Phase 4 N=130 Evaluation of Ureteral Patency in the Post-indigo Carmine Era
Ureteral Patency
Primary: Visual Analog Scale (VAS) — 48; 20; 0; 28 score on a scale
Phase 3 N=121 3,3'-Dioxo-2,2'-Bisindolylidene-5,5'-Disulfonate Disodium 0.8% Solution as an Aid for Ureteral Patency
Ureter Injury
Primary: Urine Jet Conspicuity Score — 4.1; 4.2; 2.5 score on a scale — p=<0.0001
Phase 2 N=33 Mirabegron as Medical Expulsive Therapy (MET) for Ureteral Stones and Ureteral Stent Pain
Ureteral Obstruction · Flank Pain
Primary: Spontaneous Stone Passage Using Fisher's Exact Test — 8; 5 Participants
N/A N=219 Antibiotic Prophylaxis in Percutaneous Nephrostomy Placements and Replacements for Malignant Urinary Tract Obstruction
Ureteral Obstruction · Neoplasms · Acute Kidney Injury
Primary: Urinary Tract Infection After Percutaneous Nephrostomy Procedure — 5; 10 Percutaneous nephrostomy procedure — p=0.548
Phase 2 N=125 Prospective Randomized Controlled Trial for Pain Relief After Office Ureteral Stent Removal
Pain · Urinary Stone · Urinary Calculi
Primary: Number of Participants With Unscheduled Return to Clinic or Emergency Room — 8; 1 Participants
Phase 4 N=71 The Use of Belladonna and Opium Suppository in the Treatment of Postoperative Stent Pain
Nephrolithiasis
Primary: Global Quality of Life Score on Postoperative Day 1 — 4.4; 5.4 score on a scale
N/A N=68 Renal Stent Placement for the Treatment of Renal Artery Stenosis in Patients With Resistant Hypertension
Renal Artery Stenosis · Hypertension, Renovascular
Primary: Primary Patency — 66 Subject-lesions — p=<.0001
N/A N=107 Use of The Spanner Temporary Prostatic Stent as an Alternative to a Urinary Catheter to Achieve Bladder Drainage in Men
Urinary Retention
Primary: Number of Participants Who Achieved Post-void Residual (PVR) of ≤150 ml Over 90 Days — 79 Participants
N/A N=100 Medical Expulsive Therapy of Single Distal Ureteral Stones
Ureteral Calculi
Primary: Number of Participants With Stone Expulsion — 39; 40 Participants
N/A N=95 Impact Ureteral Sheath Design During Ureteroscopy
Renal Stone · Nephrolithiasis · Urolithiasis
Primary: Number of Participants With Successful Sheath Placement — 37; 39 Participants
N/A N=158 Self-discontinuation of a Transurethral Catheter
Postoperative Urinary Retention
Primary: Number of Participants With Postoperative Urinary Retention — 11; 11 Participants — p=0.5
N/A N=49 Randomized Trial of NSAID vs Placebo Prior to Ureteral Stent Removal
Disorder of Urinary Stent · Ureteral Spasm · Ureteropelvic Junction Obstruction
Primary: Incidence of Post-operative Severe Pain (Pain Score ≥ 7) — 2; 1 Participants
N/A N=23 Prospective Evaluation of Winged Biliary Stent Patency in Patients With Benign Biliary Obstruction
Biliary Stricture
Primary: Count of Participants With Stent Patency at 90 Days — 22 Participants
N/A N=17 Comparison of Duodenal Stenting vs Transpyloric and Duodenal Stenting for Malignant Obstruction
Duodenal Obstruction
Primary: Number of Participants With Any Change (2 Point Increase or Decrease) in Symptoms From Baseline — 7; 6 Participants
N/A N=6 Covered vs Uncovered Metal Stents for Palliative Biliary Decompression in Inoperable Malignant Distal Bile Duct Obstruction
Distal Bile Duct Obstruction
Primary: Rate of Long-term Stent Failure — 0; 2 Participants
N/A N=84 Treatment for Acute Postoperative Voiding Dysfunction
Urinary Retention
Primary: Persistent Retention — 29; 21 participants
Phase 4 N=27 A Randomised Cross-over Study With Two 1-piece Urostomy Bags.
Urostomy
Primary: Preference of Sensura vs Moderma — 45; 43 percentage of prefering the product
N/A N=23 Bridge Occlusion Balloon in Lead Extraction Procedure
C.Surgical Procedure; Cardiac · Cardiac Dysrhythmia · Disorder of Pacing Function
Primary: Number of Participants With Successful Balloon Occlusion of Superior Vena Cava — 18; 5 Participants
N/A N=241 Malignant Obstruction ZILVER Against Routine Therapy (MOZART I)
Biliary Tract Neoplasms · Pancreatic Neoplasms · Jaundice, Obstructive
Primary: Patency — 110; 125.5; 121 Days — p=.057
Phase 2 N=78 Effect of Antihistamines on Ureteral Stent-Related Symptoms
Nephrolithiasis
Primary: USSQ Urinary Symptom Score — 28; 29; 16; 17 score on a scale
N/A N=379 Double-J PLUS Postmarket Registry Study
Ureter Obstruction
Primary: Percentage of Implanted Stents Meeting the Technical Success Criteria — 242; 158; 4; 2 Stent Implanted